Dr. Wilson is a seasoned biopharmaceutical industry executive with more than 25 years of experience leading and managing complex global research and development programs. As Vice President of Project Management and Strategic Initiatives, she will be charged with establishing and leading Antiva’s program management function, aligning and mobilizing cross-functional teams to drive execution of the company’s development programs. Most recently, Dr. Wilson served as Vice President, Program, Portfolio and Alliance Management (PPAM) at Revolution Medicines. During this time, she provided PPAM leadership for the company’s portfolio of oncology-focused research and development assets from startup through rapid expansion of its clinical-stage portfolio. Dr. Wilson also provided key contributions to KAI Pharmaceuticals leading up to its July 2012 acquisition by Amgen, serving as the company s Vice President, Project Management and Project Leader for KAI-4169, its lead development asset.

• 

  Vice President of Project Management & Strategic Initiatives in Antivabio

  Stopping Cancer Before It Starts